via University of Southampton
Scientists from the Antibody and Vaccine group at the University of Southampton have discovered a way to transform antibody drugs previously developed to treat autoimmunity into antibodies with powerful anti-cancer activity through a simple molecular “switch”.
This work, published in the journal Cancer Cell, focuses on a molecule called CD40 which is present on the surface of immune cells and controls both autoimmunity and cancer. In autoimmunity, CD40 is thought to be over-stimulated, increasing the chance of the immune system attacking healthy tissues; whereas in cancer, CD40 is believed to be under-stimulated, enabling tumour cells to evade the immune system. Targeting of CD40 with antibody drugs is ongoing in therapeutic interventions for both diseases.
Accordingly, antibody drugs have been developed to either activate (agonists) or suppress (antagonists) the CD40 immune pathway. Researchers at the Centre for Cancer Immunology in Southampton, led by Professors Mark Cragg and Martin Glennie now reveal that an antagonist CD40 antibody can be transformed into an agonist by simply modifying the “constant” domain of the antibody. The antagonist-turned agonist “trick” was shown for three different antagonists, being driven by the hinge part of the constant domain that controls the flexibility of the antibody. One of these antibodies, was shown to be a “super”-agonist that could stimulate the immune system and cure cancer more effectively in preclinical models than the best CD40-targeting antibody currently in clinical trial.
“Being able to toggle between an autoimmune drug and a cancer medicine with a simple switch is really exciting.” said Dr Xiaojie Yu, first author of the study. “We gained a deeper understanding of the mechanism through which CD40 becomes activated, and eagerly look forward to applying this technology to more drug candidates.”
“Our findings build on a history of CD40 research here in Southampton and were surprising and exciting in equal measure,” said Professor Mark Cragg, senior author of the study. “Taking an antibody that suppresses the immune system and turning it on its head, to activate the immune system for cancer through a relatively simple process is unprecedented. More than that, the same approach could be used for other immune targets and we look forward to seeing testing this in the near future”.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Anti-cancer treatments
- A nutrient from red meat and dairy improves the immune response against cancer
Research with animal models suggests that trans-vaccenic acid has the potential to optimize the impact of immunotherapy in oncology. Experts, however, recommend caution ...
- The pill that replaces chemotherapy
A new way of giving anti-cancer treatment is about to revolutionise life for thousands of sufferers. At present, most chemotherapy drug treatments against cancer are delivered by an intravenous ...
- Nation's insights on cancer treatment published
According to Fan Daiming, council chairman of the China Anti-Cancer Association, the publication — CACA Technical Guideline for Holistic Integrative Management of Cancer — was first published in ...
- Nutrient found in beef and dairy products found to help fight cancer
TVA – a fatty acid found in beef, lamb, and dairy products, improves the ability of immune cells to fight tumours.
- Anti-cancer Drug Navitoclax Help Treat Lower Back Pain
An existing drug that targets senescent, or sleeping cells could provide the answer to treating lower back pain, according to a new study ...
Go deeper with Google Headlines on:
Anti-cancer treatments
[google_news title=”” keyword=”anti-cancer treatments” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
CD40
- CD40/CD40L expression and its prognostic value in cervical cancer
CD40, a member of the tumor necrosis factor receptor (TNFR) family, is known to be involved in immune system regulation, acting as a costimulatory molecule, and in antitumor responses against cancer ...
- New Data on CD40 Ligand Inhibitor for Relapsing MS
And it's indeed an exciting mechanism of action. It's really novel, a new soluble CD40 ligand. We already know that it's higher in progressive MS form, in the plasma of patients who have a progressive ...
- CD40 Is Constitutively Expressed on Platelets and Provides a Novel Mechanism for Platelet Activation
CD40 is a 48-kDa phosphorylated membrane glycoprotein belonging to the tumor necrosis factor (TNF) receptor superfamily. It was first described on human bladder carcinoma cells 1 but is also expressed ...
- The CD40/CD40L costimulatory pathway in inflammatory bowel disease
The focus of this review, the CD40/CD40L costimulatory system, belongs to the TNF-TNF receptor superfamily, and will be discussed in the context of IBD pathogenesis. Comprehensive reviews on the ...
- THU0407 Preclinical Characterization of a Highly Selective and Potent Antagonistic Anti-CD40 mAb
Background Costimulatory molecule pair CD40-CD40L plays a central role not only in immune cell interactions but also in immune-non immune cell activation. Targeting this pathway has generated great ...
Go deeper with Google Headlines on:
CD40
[google_news title=”” keyword=”CD40″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]